Jan 30, 2018
Derisking is the intelligent application of early in vitro testing to investigate areas of major risk for a new molecule in development, helping to avoid spending time and resource on a compound that may carry with it a high potential liability of nonapproval or market withdrawal. Derisking provides information that allows for more informed decision-making in the high-risk arena of drug development.
In this episode, we explore how intelligent application of early in vitro testing, can help mitigate major drug development risks. We discuss the three main elements central to metabolic derisking as: drug-induced liver injury (DILI), drug-drug interactions (DDI) and metabolites in safety testing (MIST).
The original article this episode is based on was written by Guy Webber. If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: